COSM
Cosmos Health, Inc.
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic · US
$0.29
+5.19%Year over year
Reported trailing growth
- Revenue
- +33.8%
- EBITDA
- -58.4%
- EBIT
- -23.7%
- EPS
- +38.9%
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- +71.1%
- EBITDA
- +168.2%
- EPS
- +115.2%
Three-year CAGR
- Revenue
- +9.0%
- EBITDA
- -8.8%
- EBIT
- -6.4%
- Net income
- -18.3%
- EPS
- +46.2%
- Free cash flow
- -4.5%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026